期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 118, 期 -, 页码 35-51出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2017.09.003
关键词
Cancer therapy; Gene therapy; Cell-delivery vehicle; Cell therapy; Bystander effect; Suicide gene; Tumor tropism; Targeted cancer therapy; Stem cells
资金
- Ben and Catherine Ivy Foundation
- Daphna and Richard Ziman Family Foundation
- Rosalinde and Arthur Gilbert Foundation
- Alvarez Family Foundation
- Anthony F. & Susan M. Markel Foundation
- STOP Cancer
- City of Hope
- National Cancer Institute [R01CA198076, R01FD004816, U01NS082328, R43CA86768, R44CA8678, P30CA033572]
- National Cancer Institute of the National Institutes of Health [P30CA033572]
Cell-directed gene therapy is a promising new frontier for the field of targeted cancer therapies. Here we discuss the current pre-clinical and clinical use of cell-mediated enzyme prodrug therapy (EPT) directed against solid tumors and avenues for further development. We also discuss some of the challenges encountered upon translating these therapies to clinical trials. Upon sufficient development cell-mediated enzyme prodrug therapy has the potential to maximize the distribution of therapeutic enzymes within the tumor environment, localizing conversion of prodrug to active drug at the tumor sites thereby decreasing off-target toxicities. New combinatorial possibilities are also promising. For example, when combined with viral gene-delivery vehicles, this may result in new hybrid vehicles that attain heretofore unmatched levels of therapeutic gene expression within the tumor. (C) 2017 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据